Float Short %

11.66

Margin Of Safety %

-23

Put/Call OI Ratio

0.1

EPS Next Q Diff

-0.06

EPS Last/This Y

-6.45

EPS This/Next Y

0.95

Price

58.83

Target Price

69.38

Analyst Recom

1.15

Performance Q

4.51

Relative Volume

0.78

Beta

2.19

Ticker: PTGX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	PTGX	56.09	0.24	0.05	3621
2025-08-18	PTGX	56.17	0.14	0.01	2981
2025-08-19	PTGX	56.25	0.14	0.20	2999
2025-08-20	PTGX	56.21	0.14	0.00	3001
2025-08-21	PTGX	55.99	0.14	0.00	3002
2025-08-22	PTGX	57.48	0.14	0.00	3004
2025-08-25	PTGX	56.91	0.14	0.03	3011
2025-08-26	PTGX	57.23	0.14	0.00	3065
2025-08-27	PTGX	61.44	0.14	0.08	3066
2025-08-28	PTGX	58.12	0.11	0.00	3108
2025-08-29	PTGX	59	0.11	0.01	3387
2025-09-02	PTGX	58.82	0.09	0.00	3947
2025-09-03	PTGX	58.1	0.09	0.00	3972
2025-09-04	PTGX	59.4	0.09	0.00	3953
2025-09-05	PTGX	60.55	0.10	0.00	3599
2025-09-08	PTGX	56.24	0.11	1.65	3278
2025-09-09	PTGX	58.4	0.13	0.01	3362
2025-09-10	PTGX	57.72	0.10	0.00	4227
2025-09-11	PTGX	59.65	0.10	0.28	4287
2025-09-12	PTGX	58.85	0.10	0.00	4318
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	PTGX	56.08	-14.1	-	-1.98
2025-08-18	PTGX	56.19	-14.1	-	-1.98
2025-08-19	PTGX	56.25	-14.1	-	-1.98
2025-08-20	PTGX	56.24	-14.1	-	-1.98
2025-08-21	PTGX	56.04	-14.1	-	-1.98
2025-08-22	PTGX	57.53	-14.1	-	-1.98
2025-08-25	PTGX	56.91	-14.1	-	-1.98
2025-08-26	PTGX	56.99	-14.1	-	-1.98
2025-08-28	PTGX	58.14	-14.1	-	-1.98
2025-08-29	PTGX	59.05	-14.1	-	-1.98
2025-09-02	PTGX	58.83	-14.1	-	-1.98
2025-09-03	PTGX	58.12	-14.1	-	-1.98
2025-09-04	PTGX	59.62	-14.1	-	-1.98
2025-09-05	PTGX	60.53	-14.1	-	-1.98
2025-09-08	PTGX	56.19	-14.1	-	-1.98
2025-09-09	PTGX	58.39	-14.1	-	-1.98
2025-09-10	PTGX	57.73	-14.1	-	-1.98
2025-09-11	PTGX	59.68	-14.1	-	-1.98
2025-09-12	PTGX	58.83	-14.1	-	-1.98
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	PTGX	-3.98	-0.37	9.82
2025-08-18	PTGX	-3.98	0.23	9.80
2025-08-19	PTGX	-4.12	0.23	9.80
2025-08-20	PTGX	-4.12	0.23	9.80
2025-08-21	PTGX	-3.98	0.23	9.80
2025-08-22	PTGX	-3.98	0.23	9.80
2025-08-25	PTGX	-3.98	14.81	9.80
2025-08-26	PTGX	-3.98	14.81	9.80
2025-08-27	PTGX	-3.98	14.81	10.75
2025-08-28	PTGX	-3.98	14.81	10.75
2025-08-29	PTGX	-3.98	14.81	10.75
2025-09-02	PTGX	-4.08	15.10	10.74
2025-09-03	PTGX	-4.13	15.10	10.74
2025-09-04	PTGX	-4.14	15.10	10.74
2025-09-05	PTGX	-4.14	15.10	10.74
2025-09-08	PTGX	-4.14	15.15	10.74
2025-09-09	PTGX	-4.14	15.15	10.74
2025-09-10	PTGX	-4.14	15.15	10.74
2025-09-11	PTGX	-4.08	15.15	11.66
2025-09-12	PTGX	-4.08	15.15	11.66
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.55

Avg. EPS Est. Current Quarter

-0.62

Avg. EPS Est. Next Quarter

-0.61

Insider Transactions

-4.08

Institutional Transactions

15.15

Beta

2.19

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

45.47

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

4.9

Max Drawdown 5-Year %

-85.8

Target Price

69.38

P/E

82.6

Forward P/E

358.49

PEG

P/S

17.51

P/B

5.47

P/Free Cash Flow

98.7

EPS

0.71

Average EPS Est. Cur. Y

-1.98

EPS Next Y. (Est.)

-1.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

24.88

Relative Volume

0.78

Return on Equity vs Sector %

-17.1

Return on Equity vs Industry %

-3.9

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.33

EBIT Estimation

Protagonist Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 130

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today

news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance

stock history PTGX – Protagonist Therapeutics Inc invest stock market

stock prices PTGX premarket after hours

ticker PTGX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PTGX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y